TCGA-L9-A743-01A-43R-A39D-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 56
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-8299-01A-11R-2287-07 | — | cohortMD2 | 0.944 |
| 2 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.941 |
| 3 | BS_RGPSEMHC | Posterior Fossa Ependymoma | — | 0.935 |
| 4 | BS_Z28VKGNS | Neurofibroma | — | 0.933 |
| 5 | ERR2598314 | fetal | fetal | 0.931 |
| 6 | BS_1RXZ3BP7 | low-grade glioma | — | 0.929 |
| 7 | BS_JHGW42S6 | EPN | Posterior Fossa EPN | 0.929 |
| 8 | TCGA-OR-A5JO-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.928 |
| 9 | BS_FQX1PRAJ | Neurofibroma | — | 0.927 |
| 10 | SRR10842376 | — | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.450 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |